CytomX Therapeutics (CTMX) Tops Q2 EPS by 2c

CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $25.11 million versus the consensus estimate of $20 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Activist investors push Seer, Inc. to disclose go-private timeline
• Omega Flex (OFLX) Tops Q2 EPS by 27c
• Tencent Holdings (700:HK) (TCEHY) PT Lowered to HK$625 at Benchmark to Reflect Downward Earnings Revisions